Azafaros registers open-label extension trial of nizubaglustat in rare lysosomal disorders
The study, NCT07885917, is an open-label roll-over trial to evaluate long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, and Gaucher Disease Type 3. It plans to enroll 218 participants, with a start date of December 10, 2026, and primary completion by April 1, 2030.
Primary source
ClinicalTrials.gov registry record, October 21, 2026
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
Read the source: Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation